Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects



Status:Completed
Conditions:Gastrointestinal, Crohns Disease
Therapuetic Areas:Gastroenterology
Healthy:No
Age Range:18 - 55
Updated:5/20/2017
Start Date:February 28, 2011
End Date:February 18, 2015

Use our guide to learn which trials are right for you!

A Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 139 in Healthy Subjects and Subjects With Mild to Severe Crohn's Disease, and Pharmacodynamics of AMG 139 in Healthy Subjects and Subjects With Mild to Severe Crohn's Disease

The purpose of this study is to assess the safety and tolerability of AMG 139 following
multiple intravenous (IV) or subcutaneous (SC) dose administration in healthy subjects and
in subjects with mild to severe Crohn's disease (CD).


Inclusion Criteria:

Part A - Healthy Subjects:

- Healthy male or female of non-reproductive potential subjects between 18 to 45
years-of-age

- Body mass index (BMI) between 18 and 32 kg/m2

- Normal or clinically acceptable physical examination, clinical laboratory values, and
ECG

- Additional inclusion criteria apply

Part B - Crohn's Subjects:

- Male or female subjects with CD between 18 to 55 years-of-age

- Body mass index (BMI) between 18 and 32 kg/m2

- Normal or clinically acceptable physical examination (PE), clinical laboratory
values, and ECG; clinically acceptable PE includes evidence of mild to severe CD

- Diagnosis of ileal or ileo-colonic CD for a minimum of 6 months

- Mild to severe CD defined by a Crohn's Disease Activity Index (CDAI) score equal to
or greater than 180 and equal to or less than 450

- Elevated fecal calprotectin and CRP

- Additional inclusion criteria apply

Exclusion Criteria:

Parts A - Healthy Subjects:

- History or evidence of a clinically significant disorder (including psychiatric),
condition or disease that would pose a risk to subject safety or interfere with the
study evaluation, procedures or completion;

- Recent or on-going infection(s)

- Underlying condition(s) that predisposes the subject to infections

- History of malignancy of any type

- Additional exclusion criteria apply

Part B only - Crohn's Subjects:

- History or evidence of a clinically significant disorder (including psychiatric),
condition or disease that would pose a risk to subject safety or interfere with the
study evaluation, procedures or completion;

- Recent or on-going infection(s)

- Underlying condition(s) that predisposes the subject to infections

- History of malignancy of any type

- Additional exclusion criteria apply
We found this trial at
5
sites
Oklahoma City, Oklahoma 73104
?
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
175 Cross Keys Rd.
Berlin, New Jersey 08009
856-753-7335
?
mi
from
Berlin, NJ
Click here to add this to my saved trials
300c Herston Road
Herston, Queensland 4006
?
mi
from
Herston,
Click here to add this to my saved trials
Richmond, Virginia 23298
(804) 828-0100
Virginia Commonwealth University Since our founding as a medical school in 1838, Virginia Commonwealth University...
?
mi
from
Richmond, VA
Click here to add this to my saved trials
101 Nicolls Rd
Stony Brook, New York 11794
(631) 444-4000
Stony Brook University Medical Center Stony Brook Medicine expresses our shared mission of research, clinical...
?
mi
from
Stony Brook, NY
Click here to add this to my saved trials